224 results on '"Mahalingam D"'
Search Results
2. Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial
3. 1402P Initial results of a cohort of advanced prostate cancer patients in a phase Ia study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody
4. Combining ability studies for seed cotton yield in intraspecific hybrids of upland cotton (Gossypium hirsutum L.)
5. PD-016 Current results of a phase I study of DKN-01 in combination with paclitaxel (P) in patients (pts) with advanced DKK1+ esophageal cancer (EC) or gastro-esophageal junction tumors (GEJ)
6. PD-011 Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
7. 550P Initial results of a phase Ia/Ib study of NGM120, a first-in-class anti-GDNF family receptor alpha like (GFRAL) antibody in patients (pts) with advanced solid tumors
8. 1006P ACE1702, a first-in-class, off-the-shelf, selected natural killer cell [oNK] product using antibody cell conjugation technology [ACC], with pre-clinical and early clinical activity in HER2 < 3+ tumors
9. 1384P DKN-01 in combination with tislelizumab and chemotherapy as a first-line therapy in unselected patients with advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish trial
10. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
11. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers
12. 712TiP A phase I/II multicenter, open-label, dose-escalation, safety, pharmacodynamic, and pharmacokinetic study of Q901 administered via intravenous infusion in adult patients with selected advanced solid tumors with a cohort expansion at the recommended phase II dose
13. 228 (PB108) - Neratinib efficacy in patients with EGFR exon 18-mutant non-small-cell lung cancer: findings from the SUMMIT basket trial
14. COMBINATION CHEMOTHERAPY FOR PANCREATIC CANCER IN OLDER ADULTS: EFFICACY AND SAFETY ANALYSIS OF PATIENTS AT A HISPANIC-RICH NCI-DESIGNATED CANCER CENTER
15. A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
16. Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial
17. Real Time Monitoring for Drowsiness Detection using EEG System
18. A first-in-human, open-label, multicenter phase 1/2a study to evaluate the safety and efficacy of increased repeated doses of the first in class RORγ agonist LYC-55716 in treating locally advanced or metastatic solid tumors
19. P036 - COMBINATION CHEMOTHERAPY FOR PANCREATIC CANCER IN OLDER ADULTS: EFFICACY AND SAFETY ANALYSIS OF PATIENTS AT A HISPANIC-RICH NCI-DESIGNATED CANCER CENTER
20. 465P - A phase I open label dose escalation trial evaluating VT1021 in patients with advanced solid tumours
21. Prevention of neuropathy using calmangafodipir (PLEDOX):Results from a phase I study and a placebo-controlled randomized study (PLIANT) in patients with metastatic colo-rectal cancer (MCRC)
22. Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma
23. Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study
24. Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
25. 1139PD - Novel small-molecule RORγ agonist immuno-oncology agent LYC-55716: Safety and efficacy in a phase IIA open-label, multicenter trial
26. ENHANCED ANTI-TUMOR EFFICACY OF A DR5-SPECIFIC TRAIL VARIANT OVER RHTRAIL IN A BIOLUMINESCENT OVARIAN CANCER XENOGRAFT MODEL
27. CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients
28. P-175 Oncolytic Virus Therapy in Pancreatic Cancer: Clinical Efficacy and Pharmacodynamic Analysis of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma
29. 1209TiP - A first-in-human, open-label, multicenter phase 1/2a study to evaluate the safety and efficacy of increased repeated doses of the first in class RORγ agonist LYC-55716 in treating locally advanced or metastatic solid tumors
30. THU-073 - Mipsagargin, a PSMA-directed prodrug, provides clinical benefit in patients with advanced sorafenib-refractory hepatocellular carcinoma
31. 698P - Phase I study of DKN-01 (D), an anti-DKK1 monoclonal antibody, in combination with gemcitabine (G) and cisplatin (C) in patients (pts) with advanced biliary cancer (ABC)
32. 365PD - Anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody imalumab (BAX69) in advanced solid tumors: Final results of first-in-human phase 1 study
33. 555 A Study of REOLYSIN in Combination with Gemcitabine in Patients with Advanced Pancreatic Adenocarcinoma
34. 87 Inhibition of Autophagy: a Phase 1 Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Analysis of Hydroxychloroquine in Combination with the HDAC Inhibitor, Vorinostat, in Patients with Advanced Solid Tumors
35. 617 Pharmacokinetic Study of Enzastaurin in Cancer Patients with Varying Degrees of Hepatic Dysfunction
36. 601 A First-in-human, Phase 1 Clinical Study of the Safety, Tolerability and Pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated Prodrug, in Patients with Advanced Solid Tumors
37. Food Effect Study of the Investigational Aurora a Kinase (AAK) Inhibitor MLN8237 (ALISERTIB) in Patients with Advanced Solid Tumors
38. Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma
39. Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma
40. A prospective randomised study of a rotary powered device (OnControl) for bone marrow aspiration and biopsy
41. MLN4924, an investigational NEDD8-activating enzyme (NAE) inhibitor, in patients (pts) with advanced solid tumors: Phase I study of multiple treatment schedules.
42. Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function.
43. Abstract P6-14-08: Lucanthone Inhibits Autophagy and Promotes Cathepsin D-Mediated Apoptosis in Breast Cancer Cells
44. 580 Reolysin induces endoplasmic reticular stress in multiple myeloma and enhances the activity of bortezomib
45. 413 Phase II study evaluating the efficacy, safety and pharmacodynamic correlative study of dual anti-angiogenic inhibition using Bevacizumab (B) in combination with Sorafenib (S) in patients (pts) with advanced malignant melanoma
46. 586 Lucanthone: A novel inhibitor of autophagy that induces cathepsin D-mediated apoptosis
47. Effects of supplementation with tocotrienol-rich fraction on immune response to tetanus toxoid immunization in normal healthy volunteers
48. Mammalian target of rapamycin (mTOR)-induced pneumonitis: Single-institution experience and treatment.
49. Safety and pharmacokinetics (PK) of AMG 479 in combination with erlotinib (E) or sorafenib (S) in patients (pts) with advanced solid tumors.
50. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.